Human METCAM/MUC18 is a New Diagnostic Marker of and a Driver for Promoting and its Specific SiRNAs, Derived Oligopeptides and Antibodies be used for Decreasing the Malignant Progression of Prostate Cancer
Author:
Open Access
- 4 November 2016
- journal article
- Published by MedCrave Group Kft. in Journal of Stem Cell Research & Therapeutics
- Vol. 1 (5) , 1-3
Abstract
METCAM/MUC18, an integral membrane cell adhesion molecule (CAM) in the Ig-like gene superfamily, is not expressed in most normal prostate gland, or in all BPH, but overly expressed in most malignant prostate cancer. Its over-expression also correlates with the malignant progression of mouse prostatic adenocarcinoma in a TRAMP model, suggesting that it may be a diagnostic marker for malignant prostate cancer. To demonstrate this, three immunological methods are developed to show promises to use METCAM/MUC18 as a diagnostic marker for the presence of clinical prostate cancer. Enforced expression of METCAM/MUC18 in a human prostate cancer cell line, LNCaP, promotes tumorigenesis and initiates metastasis to multiple organs in a male nude mouse model, suggesting that it can promote the malignant progression of prostate cancer. ShRNAs in a lentivirus vector could decrease the tumorigenesis of another human prostate cancer cell line, DU145, in a male athymic nude mouse model. Taken together, METCAM/MUC18 is a new diagnostic marker of and a driver for promoting the malignant progression of and its specific siRNAs, oligo-peptides, and antibodies may be used for therapeutic treatments of clinical prostate cancer.Keywords
This publication has 11 references indexed in Scilit:
- Enforced Expression of METCAM/MUC18 Increases Tumorigenesis of Human Prostate Cancer LNCaP Cells in Nude MiceJournal of Urology, 2011
- Nonviral vector-mediated RNA interference: Its gene silencing characteristics and important factors to achieve RNAi-based gene therapyAdvanced Drug Delivery Reviews, 2009
- Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasisGene Therapy, 2006
- INCREASED EXPRESSION OF MUC18 CORRELATES WITH THE METASTATIC PROGRESSION OF MOUSE PROSTATE ADENOCARCINOMA IN THE TRAMP MODELJournal of Urology, 2005
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- Ectopical expression of human MUC18 increases metastasis of human prostate cancer cellsGene, 2004
- Isolation and characterization of the major form of human MUC18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progressionGene, 2001
- Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissuesThe Prostate, 2001
- Identification of bone marrow micrometastases in patients with prostate cancerCancer, 1994
- MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily.Proceedings of the National Academy of Sciences, 1989